Insider Selling: Nektar Therapeutics (NKTR) SVP Sells 20,000 Shares of Stock

Nektar Therapeutics (NASDAQ:NKTR) SVP Maninder Hora sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, April 5th. The stock was sold at an average price of $101.75, for a total transaction of $2,035,000.00. Following the transaction, the senior vice president now owns 127,394 shares of the company’s stock, valued at $12,962,339.50. The transaction was disclosed in a filing with the SEC, which is available through this link.

NASDAQ NKTR traded up $10.58 on Monday, hitting $104.45. The company’s stock had a trading volume of 2,857,513 shares, compared to its average volume of 3,136,327. Nektar Therapeutics has a 1-year low of $17.33 and a 1-year high of $111.36. The company has a debt-to-equity ratio of 2.79, a quick ratio of 5.63 and a current ratio of 5.82. The stock has a market cap of $15,105.83, a P/E ratio of -189.91 and a beta of 1.73.

How to Become a New Pot Stock Millionaire

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.14. Nektar Therapeutics had a negative net margin of 31.42% and a negative return on equity of 156.85%. The company had revenue of $95.47 million during the quarter, compared to analysts’ expectations of $36.96 million. During the same period in the prior year, the company posted ($0.28) earnings per share. Nektar Therapeutics’s revenue for the quarter was up 154.9% compared to the same quarter last year. analysts predict that Nektar Therapeutics will post -1.33 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of NKTR. Janus Henderson Group PLC increased its position in shares of Nektar Therapeutics by 87.8% during the third quarter. Janus Henderson Group PLC now owns 3,329,281 shares of the biopharmaceutical company’s stock worth $79,903,000 after buying an additional 1,556,352 shares during the period. Eagle Asset Management Inc. acquired a new stake in shares of Nektar Therapeutics during the fourth quarter worth $61,577,000. Rubric Capital Management LP acquired a new stake in shares of Nektar Therapeutics during the third quarter worth $23,924,000. Carillon Tower Advisers Inc. acquired a new stake in shares of Nektar Therapeutics during the fourth quarter worth $43,024,000. Finally, BlackRock Inc. increased its position in shares of Nektar Therapeutics by 2.1% during the fourth quarter. BlackRock Inc. now owns 21,431,388 shares of the biopharmaceutical company’s stock worth $1,279,883,000 after buying an additional 431,269 shares during the period. Institutional investors own 96.22% of the company’s stock.

Several brokerages have issued reports on NKTR. Canaccord Genuity upped their price target on shares of Nektar Therapeutics to $94.00 and gave the company a “buy” rating in a research report on Friday, March 2nd. HC Wainwright set a $125.00 price target on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Monday. Jefferies Group upped their price target on shares of Nektar Therapeutics to $103.00 and gave the company a “buy” rating in a research report on Friday, March 2nd. Mizuho restated a “buy” rating and issued a $89.00 price target on shares of Nektar Therapeutics in a research report on Wednesday, February 14th. Finally, Zacks Investment Research cut shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $63.75.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Nektar Therapeutics (NKTR) SVP Sells 20,000 Shares of Stock” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3344326/insider-selling-nektar-therapeutics-nktr-svp-sells-20000-shares-of-stock.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

8X8  Coverage Initiated by Analysts at CIBC
8X8 Coverage Initiated by Analysts at CIBC
Conatus Pharmaceuticals  Reaches New 1-Year High and Low at $3.46
Conatus Pharmaceuticals Reaches New 1-Year High and Low at $3.46
Lifetime Brands  Sets New 1-Year High and Low at $11.23
Lifetime Brands Sets New 1-Year High and Low at $11.23
Independent Bank  Announces  Earnings Results, Misses Expectations By $0.04 EPS
Independent Bank Announces Earnings Results, Misses Expectations By $0.04 EPS
Fortuna  Market Capitalization Tops $24.86 Million
Fortuna Market Capitalization Tops $24.86 Million
Axiom  Hits 24 Hour Trading Volume of $16.00
Axiom Hits 24 Hour Trading Volume of $16.00


Leave a Reply

© 2006-2018 Ticker Report. Google+.